Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): A multicenter, randomized, open-label, non-inferiority trial

Diabetes, Obesity and Metabolism

Volumn 16, Issue 8, 2014, Pages 761-765

  Kobayashi, K ^a,b   Yokoh, H ^a,b   Sato, Y ^b   Takemoto, M ^a,b   Uchida, D ^c   Kanatsuka, A ^d   Kuribayashi, N ^e   Terano, T ^f   Hashimoto, N ^g   Sakurai, K ^a,b   Hanaoka, H ^b   Ishikawa, K ^a,b   Onishi, S ^a,b   Yokote, K ^a,b   An, Tokuyoshi ^h   Tokuyama, Hirotake ^h   Bujo, Hideaki ^h   Kawamura, Harukiyo ^h   Shibata, Takahisa ^h   Tatsuno, Ichiro ^h   Ishibashi, Takayuki ^h   Nakamura, Susumu ^h   Mikami, Keiji ^h   Yamamoto, Kazuo ^h   Yamada, Kenichi ^h   Hirota, Yusuke ^h   Tadokoro, Naoko ^h   Tokuyama, Takahiko ^h   Ishibashi, Ryoichi ^h   Nakamura, Shin ^h   Tashiro, Jun ^h   Yamamoto, Kyohei ^h   Ban, Toshiaki ^h   Sano, Rie ^h   Ito, Hiroko ^h   Tanaka, Tomoaki ^h   Nishimura, Sawako ^h   Saito, Keiko ^h   Nishimura, Motonobu ^h   Fuse, Masami ^h   Mimura, Masahiro ^h   Suzuki, Sawako ^h   Tachibana, Kaori ^h   Yamada, Masahiko ^h   Ishikawa, Takahiro ^h   Nakamura, Miwako ^h   Oji, Tsuyoshi ^h   Fujimoto, Masaki ^h   more..

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

^c Hotaruno Central Clinic   (Japan)

^d Chiba Chuo Medical Center   (Japan)

^e Misaki Naika Clinic   (Japan)

^f Chiba Aoba Municipal Hospital   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^h Tokyo Women's Medical University Yachiyo Medical Center ^*

Author keywords

DPP IV inhibitor; Randomized trial; Sulphonylureas; Type 2 diabetes; glucosidase inhibitor

Indexed keywords

GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; MIGLITOL; SITAGLIPTIN; SULFONYLUREA; VOGLIBOSE; 1 DEOXYNOJIRIMYCIN; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GASTROINTESTINAL AGENT; GLYCOSIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INOSITOL; PYRAZINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREAS ISLET CELL FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; FEMALE; HYPERGLYCEMIA; JAPAN; MALE; METABOLISM; MIDDLE AGED;

1-DEOXYNOJIRIMYCIN; AGED; ALPHA-GLUCOSIDASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; GLYCOSIDE HYDROLASE INHIBITORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INOSITOL; JAPAN; MALE; MIDDLE AGED; PYRAZINES; SULFONYLUREA COMPOUNDS; TRIAZOLES;

EID: 84904395436     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12264     Document Type: Article

References (12)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
2. Arai K, Matoba K, Hirao K et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
3. Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
4. Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell 2012; 148: 1160-1171.
5. Raz I, Hanefeld M, Xu L et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.
6. Tajima N, Kadowaki T, Odawara M, Nishii M, Taniguchi T, Arjona Ferreira JC. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52weeks leads to improved glycemic control. Diabetol Int 2011; 2: 32-44.
7. Kawamori R, Tajima N, Iwamoto Y et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009; 373: 1607-1614.
8. Dungan KM, Buse JB, Largay J et al. 1, 5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006; 29: 1214-1219.
9. Iwamoto Y, Tajima N, Kadowaki T et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010; 12: 613-622.
10. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.
11. Pan C, Yang W, Barona JP et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008; 25: 435-441.
12. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.